Eledon Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2016
Filed with the SEC on Mar 3, 2017 and accepted by EDGAR at Mar 3, 2017, 16:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-10-01 to 2016-12-31 | $0 | us-gaap:SalesRevenueGoodsNet |
| Revenue | 12 months2016-01-01 to 2016-12-31 | $0 | us-gaap:Revenues |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $25.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-10-01 to 2016-12-31 | −$3.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2016-01-01 to 2016-12-31 | −$38.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2016-01-01 to 2016-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-10-01 to 2016-12-31 | −$3.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2016-01-01 to 2016-12-31 | −$38.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-10-01 to 2016-12-31 | −$0.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | −$1.68 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | −$36.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $17.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-12-31 | $23.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $29.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $29.8m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $2.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $2.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-12-31 | $26.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-17-069741. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.